Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Value in health 2014-11, Vol.17 (7), p.A638-A638
Hauptverfasser: Garcia Lopez, J.L, Rodriguez, Barrios J.M, Puig-Junoy, J, Carrato, Mena A
Format: Artikel
Sprache:eng
Schlagworte:
Internal Medicine
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page A638
container_issue 7
container_start_page A638
container_title Value in health
container_volume 17
creator Garcia Lopez, J.L
Rodriguez, Barrios J.M
Puig-Junoy, J
Carrato, Mena A
description
doi_str_mv 10.1016/j.jval.2014.08.2298
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1790459508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1098301514042284</els_id><sourcerecordid>1790459508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2508-c73d0ad97468b42dce90133f64b6afb0f6ee1a308e9ab83f242afd0f499807f63</originalsourceid><addsrcrecordid>eNo9kctu1DAUQCMEoqXwBUjISxYkXD-S2BukMkwLUiUQLWvLca6FByceYmdg-gP8NommsPK1dO7zFMVLChUF2rzdVbuDCRUDKiqQFWNKPirOac1EKVrOHy8xKFlyoPVZ8SylHQA0nNVPizPWMmCsVefFn01Mudw6hzb7A46YErkcTTgmn0h05D0ejPX382C6N-QqZhzmlP2IxIw92f7OOPbYlx9iQnKHQ7yPIQ6-R-JH8sVkj2NO5JfP38lXtPM0LX9yHXzsgkk5DmblbvfGj8-LJ86EhC8e3ovi29X2bvOxvPl8_WlzeVNaVoMsbct7ML1qRSM7wXqLCijnrhFdY1wHrkGkhoNEZTrJHRPMuB6cUEpC6xp-Ubw-1d1P8eeMKevBJ4shmBHjnDRtFYhaLb0WlJ9QO8WUJnR6P_nBTEdNQa8G9E6vBvRqQIPUq4El69VDg7kbsP-f8-_kC_DuBOCy5sHjpG3wo7cm_MAjpl2cp-X-yyQ6MQ36dpW4OqQCBGNS8L-8NZpJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1790459508</pqid></control><display><type>article</type><title>Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Garcia Lopez, J.L ; Rodriguez, Barrios J.M ; Puig-Junoy, J ; Carrato, Mena A</creator><creatorcontrib>Garcia Lopez, J.L ; Rodriguez, Barrios J.M ; Puig-Junoy, J ; Carrato, Mena A</creatorcontrib><identifier>ISSN: 1098-3015</identifier><identifier>EISSN: 1524-4733</identifier><identifier>DOI: 10.1016/j.jval.2014.08.2298</identifier><identifier>PMID: 27202279</identifier><language>eng</language><publisher>United States</publisher><subject>Internal Medicine</subject><ispartof>Value in health, 2014-11, Vol.17 (7), p.A638-A638</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2508-c73d0ad97468b42dce90133f64b6afb0f6ee1a308e9ab83f242afd0f499807f63</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27202279$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garcia Lopez, J.L</creatorcontrib><creatorcontrib>Rodriguez, Barrios J.M</creatorcontrib><creatorcontrib>Puig-Junoy, J</creatorcontrib><creatorcontrib>Carrato, Mena A</creatorcontrib><title>Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain</title><title>Value in health</title><addtitle>Value Health</addtitle><subject>Internal Medicine</subject><issn>1098-3015</issn><issn>1524-4733</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNo9kctu1DAUQCMEoqXwBUjISxYkXD-S2BukMkwLUiUQLWvLca6FByceYmdg-gP8NommsPK1dO7zFMVLChUF2rzdVbuDCRUDKiqQFWNKPirOac1EKVrOHy8xKFlyoPVZ8SylHQA0nNVPizPWMmCsVefFn01Mudw6hzb7A46YErkcTTgmn0h05D0ejPX382C6N-QqZhzmlP2IxIw92f7OOPbYlx9iQnKHQ7yPIQ6-R-JH8sVkj2NO5JfP38lXtPM0LX9yHXzsgkk5DmblbvfGj8-LJ86EhC8e3ovi29X2bvOxvPl8_WlzeVNaVoMsbct7ML1qRSM7wXqLCijnrhFdY1wHrkGkhoNEZTrJHRPMuB6cUEpC6xp-Ubw-1d1P8eeMKevBJ4shmBHjnDRtFYhaLb0WlJ9QO8WUJnR6P_nBTEdNQa8G9E6vBvRqQIPUq4El69VDg7kbsP-f8-_kC_DuBOCy5sHjpG3wo7cm_MAjpl2cp-X-yyQ6MQ36dpW4OqQCBGNS8L-8NZpJ</recordid><startdate>201411</startdate><enddate>201411</enddate><creator>Garcia Lopez, J.L</creator><creator>Rodriguez, Barrios J.M</creator><creator>Puig-Junoy, J</creator><creator>Carrato, Mena A</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201411</creationdate><title>Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain</title><author>Garcia Lopez, J.L ; Rodriguez, Barrios J.M ; Puig-Junoy, J ; Carrato, Mena A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2508-c73d0ad97468b42dce90133f64b6afb0f6ee1a308e9ab83f242afd0f499807f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Internal Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garcia Lopez, J.L</creatorcontrib><creatorcontrib>Rodriguez, Barrios J.M</creatorcontrib><creatorcontrib>Puig-Junoy, J</creatorcontrib><creatorcontrib>Carrato, Mena A</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Value in health</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garcia Lopez, J.L</au><au>Rodriguez, Barrios J.M</au><au>Puig-Junoy, J</au><au>Carrato, Mena A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain</atitle><jtitle>Value in health</jtitle><addtitle>Value Health</addtitle><date>2014-11</date><risdate>2014</risdate><volume>17</volume><issue>7</issue><spage>A638</spage><epage>A638</epage><pages>A638-A638</pages><issn>1098-3015</issn><eissn>1524-4733</eissn><cop>United States</cop><pmid>27202279</pmid><doi>10.1016/j.jval.2014.08.2298</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1098-3015
ispartof Value in health, 2014-11, Vol.17 (7), p.A638-A638
issn 1098-3015
1524-4733
language eng
recordid cdi_proquest_miscellaneous_1790459508
source Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals
subjects Internal Medicine
title Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients with Recurrent Glioblastoma in Spain
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T20%3A02%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-Effectiveness%20Analysis%20of%20Bevacizumab,%20Fotemustine%20and%20Extended-Dose%20Temozolomide%20in%20Patients%20with%20Recurrent%20Glioblastoma%20in%20Spain&rft.jtitle=Value%20in%20health&rft.au=Garcia%20Lopez,%20J.L&rft.date=2014-11&rft.volume=17&rft.issue=7&rft.spage=A638&rft.epage=A638&rft.pages=A638-A638&rft.issn=1098-3015&rft.eissn=1524-4733&rft_id=info:doi/10.1016/j.jval.2014.08.2298&rft_dat=%3Cproquest_cross%3E1790459508%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1790459508&rft_id=info:pmid/27202279&rft_els_id=1_s2_0_S1098301514042284&rfr_iscdi=true